FY2025 EPS Estimates for TSHA Lowered by Cantor Fitzgerald

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Equities research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Taysha Gene Therapies in a research note issued on Wednesday, August 13th. Cantor Fitzgerald analyst K. Kluska now expects that the company will earn ($0.38) per share for the year, down from their previous estimate of ($0.33). Cantor Fitzgerald currently has a “Overweight” rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.35) per share. Cantor Fitzgerald also issued estimates for Taysha Gene Therapies’ FY2026 earnings at ($0.52) EPS.

TSHA has been the topic of several other reports. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. JMP Securities raised their price objective on Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a “market outperform” rating in a report on Thursday, May 29th. Bank of America began coverage on Taysha Gene Therapies in a report on Friday, July 11th. They set a “buy” rating and a $8.00 price objective on the stock. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, July 1st. Finally, Wells Fargo & Company raised their price objective on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a report on Wednesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies has an average rating of “Buy” and a consensus price target of $8.29.

Taysha Gene Therapies Stock Performance

TSHA opened at $2.94 on Friday. The stock’s fifty day moving average is $2.60 and its two-hundred day moving average is $2.12. The company has a market capitalization of $631.11 million, a P/E ratio of -8.65 and a beta of 0.98. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $3.31. The company has a quick ratio of 5.35, a current ratio of 12.48 and a debt-to-equity ratio of 0.17.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.02). The firm had revenue of $1.99 million for the quarter, compared to analysts’ expectations of $1.61 million. Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.

Insider Transactions at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 750,000 shares of the company’s stock in a transaction on Friday, May 30th. The shares were acquired at an average price of $2.75 per share, with a total value of $2,062,500.00. Following the transaction, the insider owned 2,841,704 shares of the company’s stock, valued at $7,814,686. The trade was a 35.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 3.78% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently made changes to their positions in the business. Ground Swell Capital LLC acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $25,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $31,000. Hsbc Holdings PLC boosted its position in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after purchasing an additional 8,076 shares in the last quarter. May Hill Capital LLC acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $37,000. Finally, Ameriprise Financial Inc. acquired a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $40,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.